anastrozole tablet
breckenridge pharmaceutical, inc. - anastrozole (unii: 2z07myw1az) (anastrozole - unii:2z07myw1az) - anastrozole 1 mg - anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with er-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets. hypersensitivity anastrozole tablets are contraindicated in any patient who has shown a hypersensitivity reaction to the drug or to any of the excipients. observed reactions include anaphylaxis, angioedema, and urticaria [see adverse reactions (6.2)]. risk summary based on findings from animal studies and its mechanism of action, anastrozole tablets may cause fetal harm when administered to a pregnant
anastrozole tablet
rising pharmaceuticals, inc. - anastrozole (unii: 2z07myw1az) (anastrozole - unii:2z07myw1az) - anastrozole 1 mg - anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with er-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets. hypersensitivity anastrozole tablets are contraindicated in any patient who has shown a hypersensitivity reaction to the drug or to any of the excipients. observed reactions include anaphylaxis, angioedema, and urticaria. [see adverse reactions (6.2)] risk summary based on findings from animal studies and its mechanism of action, anastrozole tablets may cause fetal harm when administered to a pr
anastrozole tablet, film coated
apotex corp. - anastrozole (unii: 2z07myw1az) (anastrozole - unii:2z07myw1az) - anastrozole 1 mg - anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with er-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets. hypersensitivity anastrozole tablets are contraindicated in any patient who has shown a hypersensitivity reaction to the drug or to any of the excipients. observed reactions include anaphylaxis, angioedema, and urticaria [see adverse reactions (6.2)]. risk summary based on findings from animal studies and its mechanism of action, anastrozole may cause fetal harm when administered to a pregnant woman [s
anastrozole tablet, film coated
golden state medical supply - anastrozole (unii: 2z07myw1az) (anastrozole - unii:2z07myw1az) - anastrozole 1 mg - anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with er-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets. hypersensitivity anastrozole tablets are contraindicated in any patient who has shown a hypersensitivity reaction to the drug or to any of the excipients. observed reactions include anaphylaxis, angioedema, and urticaria [see adverse reactions ( 6.2)]. risk summary based on findings from animal studies and its mechanism of action, anastrozole may cause fetal harm when admini
anastrozole tablet
pd-rx pharmaceuticals, inc. - anastrozole (unii: 2z07myw1az) (anastrozole - unii:2z07myw1az) - anastrozole 1 mg - anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with er-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets. hypersensitivity anastrozole tablets are contraindicated in any patient who has shown a hypersensitivity reaction to the drug or to any of the excipients. observed reactions include anaphylaxis, angioedema, and urticaria [see adverse reactions (6.2)]. risk summary based on findings from animal studies and its mechanism of action, anastrozole tablets may cause fetal harm
anastrozole tablet
rebel distributors corp - anastrozole (unii: 2z07myw1az) (anastrozole - unii:2z07myw1az) - anastrozole 1 mg - anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with er-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets. anastrozole tablets may cause fetal harm when administered to a pregnant woman and offers no clinical benefit to premenopausal women with breast cancer. anastrozole tablets are contraindicated in women who are or may become pregnant. there are no adequate and well controlled studies in pregnant women using anastrozole tablets. if anastrozole tablets are used during pregnancy, or if the patient becomes
anastrozole tablet
stason pharmaceuticals, inc - anastrozole (unii: 2z07myw1az) (anastrozole - unii:2z07myw1az) - anastrozole 1 mg - anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with er-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole. anastrozole may cause fetal harm when administered to a pregnant woman and offers no clinical benefit to premenopausal women with breast cancer. anastrozole is contraindicated in women who are or may become pregnant. there are no adequate and well-controlled studies in pregnant women using anastrozole. if anastrozole is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of th
anastrozole fbm anastrozole 1mg tablet blister pack
southern cross pharma pty ltd - anastrozole, quantity: 1 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; titanium dioxide; lactose monohydrate; magnesium stearate; hydrogenated cottonseed oil; hypromellose; macrogol 6000; pregelatinised maize starch; povidone - early breast cancer. adjuvant treatment of early breast cancer in postmenopausal women with oestrogen/progesterone receptor positive disease. advanced breast cancer. first line treatment of advanced breast cancer in postmenopausal women with oestrogen/progesterone receptor positive disease. treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with oestrogen receptor negative disease and patients who have not responded to previous tamoxifen therapy rarely respond to anastrozole.
anastrozole-gh anastrozole 1 mg film-coated tablet blister pack
generic health pty ltd - anastrozole, quantity: 1 mg - tablet, film coated - excipient ingredients: magnesium stearate; povidone; sodium starch glycollate; lactose monohydrate; titanium dioxide; hypromellose; macrogol 400 - early breast cancer. adjuvant treatment of early breast cancer in postmenopausal women with oestrogen/ progesterone receptor positive disease.. advanced breast cancer. first line treatment of advanced breast cancer in postmenopausal women with oestrogen/ progesterone receptor positive disease.. treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with oestrogen receptor negative disease and patients who have not responded to previous tamoxifen therapy rarely respond to anastrozole.
anastrozole sandoz anastrozole 1 mg tablet blister pack
sandoz pty ltd - anastrozole, quantity: 1 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; hyprolose; magnesium stearate; microcrystalline cellulose; sodium starch glycollate type a; lactose monohydrate; titanium dioxide; hypromellose; macrogol 4000 - early breast cancer: adjuvant treatment of early breast cancer in post-menopausal women with estrogen/progesterone receptor positive disease. advanced breast cancer: first line treatment of advanced breast cancer in post-menopausal women with estrogen/progesterone receptor positive disease. treatment of advanced breast cancer in post-menopausal women with disease progression following tamoxifen therapy. patients with estrogen-receptor-negative disease and patients who have not responded to previous tamoxifen therapy rarely respond to anastrozole.